Anti-Insulin Receptor Autoantibodies Are Not Required for Type 2 Diabetes Pathogenesis in NZL/Lt Mice, a New Zealand Obese (NZO)-Derived Mouse Strain
2004

Anti-Insulin Receptor Autoantibodies and Type 2 Diabetes in Mice

Sample size: 33 publication 15 minutes Evidence: moderate

Author Information

Author(s): Marcia F. McInerney, Sonia M. Najjar, Deanna Brickley, Mary Lutzke, George A. Abou-Rjaily, Peter Reifsnyder, Bradford D. Haskell, Kevin Flurkey, Ying-Jian Zhang, Susan L. Pietropaolo, Massimo Pietropaolo, James P. Byers, Edward H. Leiter

Primary Institution: University of Toledo College of Pharmacy

Hypothesis

Are anti-insulin receptor autoantibodies required for the development of type 2 diabetes in NZO mice?

Conclusion

Anti-insulin receptor autoantibodies are not essential for the development of insulin resistance or diabetes in NZO mice.

Supporting Evidence

  • 50% of NZO/HlLt males develop diabetes by 24 weeks.
  • B lymphocyte-deficient mice did not show significant differences in diabetes development compared to wild-type.
  • Autoantibodies were present in diabetic but not normoglycemic mice.

Takeaway

The study found that certain antibodies in mice don't actually cause diabetes, even though they are often thought to be linked.

Methodology

The study involved creating a new mouse strain and comparing the development of diabetes in mice with and without specific autoantibodies.

Potential Biases

Potential bias due to the specific genetic backgrounds of the mouse strains used.

Limitations

The study's findings may not be generalizable beyond the specific mouse strains used.

Participant Demographics

NZO/HlLt male and female mice, aged 16 to 28 weeks.

Statistical Information

P-Value

<0.0005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1080/15438600490478029

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication